Compare Ginkgo Bioworks Holdings Inc (DNA) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Kohl's Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Kohl's Corporation trades at $16.38 (market cap $1.86B). The key difference: Kohl's Corporation is far larger — about 3.1× Ginkgo Bioworks Holdings Inc's market cap, and Kohl's Corporation pays a 3.04% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | KSS | |
|---|---|---|
Market Cap | $590.53M | $1.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $24.71 |
52-Week Low | $5.48 | $9.27 |
Enterprise Value | $627.78M | $7.97B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Kohl's (KSS) trades at $16.55, down 1.49% today, showing mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 6.95 and P/B of 0.47. Recent earnings have consistently beaten expectations, with Q1 2026 showing early turnaround progress despite revenue declines. The company maintains a 40.52% gross margin and positive cash flow from operations of $648M in 2025, while implementing strategic changes including new leadership appointments and proprietary brand expansion.
KSS presents a value opportunity with deep discount valuations, though facing significant headwinds from declining revenues and competitive pressures. The stock's near-term trajectory depends on successful execution of turnaround initiatives and proprietary brand growth, with analyst consensus at $16.75 offering modest upside potential from current levels amid cautious market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
